SCHEMBL10022672

SCHEMBL10022672

Cc1cncc(-c2ncc(C(=O)O)s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.50
CDC7 O00311 1/20 0.43
DBF4 Q9UBU7 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 3/20 0.42
POLB P06746 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
ICAM1 P05362 1/20 0.39
SELE P16581 1/20 0.39
VCAM1 P19320 1/20 0.39
ATM Q13315 1/20 0.39
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
CYP2A6 P11509 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10066392 0.83 CYP11B1 (0.40) HCAR2CDC7DBF4CYP11B1CYP11B2
SCHEMBL23794763 0.80 HSD17B1 (0.57) HCAR2NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4283912 0.79 HCAR2 (0.55) HCAR2CDC7DBF4NPC1RAB9A
SCHEMBL10066410 0.76 CYP11B1 (0.45) HCAR2CYP11B1CYP11B2NPC1RAB9A
SCHEMBL23794673 0.76 HCAR2 (0.44) HCAR2CDC7DBF4NPC1RAB9A
SCHEMBL22617518 0.75 HCAR2 (0.46) HCAR2CYP11B1CYP11B2RAB9ASMN1; SMN2
SCHEMBL324719 0.74 CDC7 (0.49) HCAR2CDC7DBF4NPC1RAB9A
SCHEMBL3593476 0.73 CDC7 (0.63) HCAR2CDC7DBF4NPC1RAB9A
SCHEMBL20894394 0.73 HCAR2 (0.51) HCAR2CDC7DBF4NPC1RAB9A
SCHEMBL1421843 0.73 MKNK1 (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590950-B1 N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-10-15 EP disclosed
US-20120165322-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 US disclosed
US-20120165322-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165322-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA HCAR2 2002/4885CDC7 567/4885DBF4 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.